检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《山西医药杂志》2007年第2期118-120,共3页Shanxi Medical Journal
摘 要:目的探讨血清超氧化物歧化酶(SOD)活力、丙二醛(MDA)含量在恶性血液病中的变化规律及临床意义。方法采用黄嘌呤氧化酶法测定SOD活力,采用硫代巴比妥酸化学比色法测定MDA含量。结果治疗前急性白血病、慢性粒细胞白血病和多发性骨髓瘤组血清SOD活力明显低于正常组(P<0.05),非霍奇金淋巴瘤组血清SOD活力与正常组相比差异无统计学意义(P>0.05);急性白血病、慢性粒细胞白血病、多发性骨髓瘤和非霍奇金淋巴瘤组血清MDA含量均明显高于正常组(P<0.05)。14例急性白血病和8例多发性骨髓瘤患者经治疗病情缓解后血清SOD活力较治疗前明显升高(P<0.05),MDA含量明显下降(P<0.05)。结论自由基—脂质过氧化反应参与了恶性血液病的发生、发展,动态监测血清SOD活力和MDA含量的变化,对观察恶性血液病病情变化、判断预后有重要的临床意义。Objective To study the regulating rule and clinical significance of serum superoxide dismutase (SOD) and malondialdehyde (MDA) in malignant hematologic disease. Methods The activity of SOD was measured by xanthine oxidase method. The levels of MDA were determined by thioharbituric acid colorimetry. Results The activity of SOD before treatment in patients with acute leukemia, chronic myelocytic leukemia and multiple myeloma was significantly lower than that in controls (P(0.05) and there was no significant difference between non Hodgkin's lymphoma patients and controls ( P 〉 0.05). At the same time, the levels of MDA in patients with acute leukemia, chronic myelocytic leukemia, multiple myeloma and non Hodgkin's lymphoma were significantly higher than that in controls ( P 〈0.05). After treatment, with the patients'recovery, the activity of SOD in 14 cases of acute leukemia patients and 8 cases of multiple myeloma patients was significantly higher compared with that before treatment (P 〈 0.05 ), the levels of MDA were significantly lower compared with that before treatment (P 〈 0.05). Conclusion Radical-lipid peroxidation plays an important role in the occurrence and the development of malignant hematologic diseases. The changes of SOD and MDA would predtict the disease development and prognosis in malignant hematologic diseases.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.173